Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. Chief Commercial Officer Brian B. Hansen reported equity awards consisting of restricted stock units and stock options. He received 90,253 RSUs, each representing one share of common stock, bringing his direct common stock holdings to 132,357 shares after the grant.
He was also granted 124,193 employee stock options with an exercise price of $5.54 per share, all held directly, with 124,193 options outstanding after the award. The RSUs vest in eight equal installments starting on June 15, 2026, then every six months from November 15, 2026. The options vest in 48 equal monthly installments starting on May 19, 2026. All share amounts reflect a 1-for-20 reverse stock split effective October 17, 2025.
Senseonics Holdings, Inc. President and CEO Timothy T. Goodnow reported receiving equity awards consisting of restricted stock units and stock options. He was granted 553,701 RSUs, each representing one share of common stock, which vest in eight equal installments starting on June 15, 2026 and then every six months beginning November 15, 2026, subject to continued service.
Goodnow was also granted 761,923 employee stock options to purchase common stock at an exercise price of $5.54 per share, vesting in 48 equal monthly installments beginning on May 19, 2026 and expiring on May 18, 2036, also contingent on continued service. Following the RSU grant, his reported direct common stock holdings total 1,176,346 shares.
Senseonics Holdings, Inc. held its 2026 annual meeting, where stockholders approved doubling the authorized common stock from 70,000,000 to 140,000,000 shares through a charter amendment effective May 20, 2026. Stockholders also elected three directors, approved executive pay on an advisory basis, and chose to hold say‑on‑pay votes annually.
They ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, approved the charter amendment increasing authorized shares, and adopted the Senseonics Holdings, Inc. 2026 Equity Incentive Plan. At the meeting, 23,650,239 shares, or 56.59% of the 41,795,466 shares outstanding as of the record date, were present or represented by proxy.
Senseonics Holdings, Inc. Chief Financial Officer reports routine tax withholding on vested stock units. On the reported date, Frederick T. Sullivan had 9,005 shares of common stock withheld at $5.82 per share to cover withholding tax obligations tied to the vesting of restricted stock units. These are not open-market sales, but shares retained by the company for tax payment. After this transaction, he directly holds 141,621 shares of Senseonics common stock.
Senseonics Holdings, Inc. director and Chief Medical Officer Francine Kaufman reported a tax-related share disposition tied to equity compensation. On this Form 4, 6,058 shares of common stock were withheld at $5.82 per share to cover withholding tax obligations upon the vesting of restricted stock units. After this withholding, Kaufman directly holds 117,890 shares of Senseonics common stock.
Senseonics Holdings Chief Operating Officer Mukul Jain reported a routine tax-related share withholding. On the vesting of restricted stock units, 13,681 shares of common stock were withheld at $5.82 per share to satisfy withholding tax obligations. Following this non-market transaction, he directly holds 246,298 shares of Senseonics common stock.
Senseonics Holdings, Inc. President and CEO Timothy T. Goodnow reported a routine tax-related share disposition. On the vesting of restricted stock units, 28,598 shares of common stock were withheld at $5.82 per share to cover withholding tax obligations. After this transaction, he directly holds 622,645 shares of Senseonics common stock.
Senseonics Holdings, Inc. reported that GC & Corp. Development Advisor Kenneth L. Horton had 7,320 shares of common stock withheld on May 15, 2026 to cover withholding tax obligations from vesting restricted stock units. After this tax-withholding disposition, he directly holds 137,114 shares of Senseonics common stock.
Senseonics Holdings director Douglas A. Roeder bought additional shares of the company’s common stock in an open-market transaction. On this trade, he purchased 22,686 shares at a price of $5.56 per share. After the transaction, he directly holds 144,635 shares of Senseonics common stock.
Senseonics Holdings, Inc. reported higher sales but wider losses for the quarter ended March 31, 2026 as it internalizes commercialization of its Eversense implantable CGM systems.
Total revenue rose to $11.7 million from $6.3 million a year earlier, driven mainly by U.S. sales now representing nearly 80% of revenue. However, operating expenses increased sharply, leading to a net loss of $32.3 million, compared with a $14.3 million loss in the prior-year quarter. Cash, cash equivalents and marketable securities were $64.3 million as of March 31, 2026. Subsequent to quarter end, the company raised an estimated $86.0 million net through an underwritten equity offering and secured access to up to $140.0 million in term loans, and management concluded that prior substantial doubt about its ability to continue as a going concern has been alleviated.